Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer commences new prostate cancer drug trial

Bayer commences new prostate cancer drug trial

3rd June 2016

Bayer and collaborative partner Orion have begun a new clinical trial assessing the potential of a new prostate cancer therapy.

The phase III study ARASENS will assess the investigational androgen receptor antagonist BAY-1841788, also known as ODM-201, in combination with standard androgen deprivation therapy and the chemotherapy docetaxel in men with newly diagnosed metastatic hormone-sensitive prostate cancer, starting first-line hormone therapy.

Offering a unique chemical structure, the compound has been designed to block the growth of cancer cells through binding to the androgen receptor with high affinity and inhibiting its function. It is also being studied as a treatment for high-risk non-metastatic castration-resistant prostate cancer.

The ARASENS trial is expected to start the enrollment of patients towards the end of 2016.

Dr Joerg Moeller, member of the executive committee of Bayer's pharmaceutical division and head of development, said: "Bayer's commitment to prostate cancer research runs deep, and the initiation of ARASENS is the latest in a long line of studies designed to evaluate treatment options for patients with advanced disease."

Bayer will commercialise the product globally, while Orion has the option to co-promote it in Europe and is additionally responsible for manufacturing.ADNFCR-8000103-ID-801819681-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.